Robert Haddad, MD
Medical Oncology · Boston, MANPI 1942259098
Payments from drug & device makers
Across 706 payments — averaging $6411.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.4M
- AstraZeneca$790K
- Incyte Corporation$784K
- AVEO Pharmaceuticals, Inc.$631K
- E.r. Squibb & Sons, L.L.C.$270K
- GSK$162K
- plus $459K from 22 others
Across 15 payments — averaging $3494.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$43K
- Bristol Myers Squibb$6K
- F. Hoffmann-la Roche AG$3K
- Boehringer Ingelheim International GmbH$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 270 | $1,431,664 |
| AstraZeneca | 17 | $790,341 |
| Incyte Corporation | 149 | $783,751 |
| AVEO Pharmaceuticals, Inc. | 31 | $630,651 |
| E.r. Squibb & Sons, L.L.C. | 27 | $269,804 |
| GSK | 54 | $161,561 |
| Pfizer | 16 | $121,349 |
| Genentech, Inc. | 10 | $70,886 |
| Exelixis Inc. | 16 | $45,970 |
| Bayer | 19 | $30,098 |
| Hikma Pharmaceuticals USA | 10 | $29,785 |
| Boehringer Ingelheim International GmbH | 15 | $29,355 |
| Astrazeneca UK Limited | 15 | $28,681 |
| Eisai Inc. | 20 | $28,675 |
| EMD Serono, Inc. | 8 | $20,285 |
| Genmab U.S., Inc. | 4 | $13,634 |
| Merck Kgaa | 3 | $7,417 |
| Coherus Oncology, Inc. | 6 | $6,938 |
| F. Hoffmann-la Roche AG | 3 | $5,832 |
| Janssen Research & Development, LLC | 2 | $4,335 |
| AbbVie | 2 | $3,693 |
| Gilead | 1 | $3,610 |
| G1 Therapeutics, Inc. | 1 | $3,480 |
| Janssen Scientific Affairs, LLC | 2 | $2,644 |
| Beigene USA, Inc. | 1 | $1,500 |
| Johnson & Johnson | 1 | $705 |
| Ascendis Pharma Endocrinology Inc | 1 | $112 |
| Roche Products Limited | 2 | $46 |
How this compares
$4,526,801 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Boston
- Otto MetzgerBoston$141.9M
- Suzanne GeorgeBoston$88.5M
- Pasi Antero JanneBoston$67.2M
- Erica MayerBoston$51.8M
- Toni ChoueiriBoston$28.3M
- Laura SpringBoston$22.9M
- James ClearyBoston$18.8M
- Marlise LuskinBoston$18.7M
- Ana Garrido-CastroBoston$18M
- Jacob LaubachBoston$17.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.